NCT06633042 is a Phase 1 clinical trial of Universal BCMA-CD19 CART in Autoimmune Disease, sponsored by Bioray Laboratories.

Who is sponsoring NCT06633042?

NCT06633042 is sponsored by Bioray Laboratories.

What drugs are being tested in NCT06633042?

Interventions in NCT06633042: Universal BCMA-CD19 CART.

What condition does NCT06633042 study?

NCT06633042 studies Autoimmune Disease.

Is NCT06633042 still recruiting?

NCT06633042 is currently not yet recruiting. Last updated 12 November 2024.

Last reviewed 2024-11-12 · How we verify

NCT06633042

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Safety and Efficacy of Universal CAR-T Cells Targeting BCMA in the Treatment of Refractory NMOSD

Not yet recruiting Phase 1 Last updated 12 November 2024

What this trial tests

Phase 1 trial testing Universal BCMA-CD19 CART in Autoimmune Disease in 18 participants. Not yet recruiting.

Timeline

25 November 2024

Primary endpoint
12 October 2025

12 December 2025

Quick facts

Lead sponsor	Bioray Laboratories
Phase	Phase 1
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	na
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	18
Start date	25 November 2024
Primary completion	12 October 2025
Estimated completion	12 December 2025

Drugs / interventions tested

Universal BCMA-CD19 CART — full drug profile →

Conditions studied

Autoimmune Disease — all drugs for Autoimmune Disease →

Sponsor

Bioray Laboratories — full company profile →

Who can join

Adults 18 to 65, any sex, with Autoimmune Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is an open label, Multi-center，dose-escalation study in up to 18 participants with refractory NMOSD. This study aims to evaluate the safety and efficacy of universal CAR-T Cells targeting BCMA in the Treatment of refractory NMOSD.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

CAR T-cell therapy in autoimmune diseases: a promising frontier on the horizon.
Wu D, Xu-Monette ZY, Zhou J, Yang K, et al · · 2025 · cited 9× · PMID 40873568 · DOI 10.3389/fimmu.2025.1613878
Advancing gene editing therapeutics: Clinical trials and innovative delivery systems across diverse diseases.
Raigani M, Eftekhari Z, Adeli A, Kazemi-Lomedasht F. · · 2025 · cited 5× · PMID 40896588 · DOI 10.1016/j.omtn.2025.102666
Chimeric Antigen Receptor T-Cell Therapy and Autoimmune Diseases in the Nervous System.
Yao SY, Du MQ, Yang H, Zeng QM, et al · · 2025 · cited 2× · PMID 41208643 · DOI 10.1002/iid3.70298
Induction of immune tolerance in NMOSD and MOGAD.
Correale J, Carnero Contentti E. · · 2025 · cited 2× · PMID 40761287 · DOI 10.1177/17562864251357393
Research progress on chimeric antigen receptor-based immunotherapy against autoimmune diseases.
Jiang M, Zhao J, Yuan J, Yu Z, et al · · 2025 · cited 2× · PMID 40747591 · DOI 10.1080/21645515.2025.2538350
Roads and detours for CAR T cell therapy in autoimmune diseases.
Avouac J, Barzel A, Caiati D, Davis RS, et al · · 2026 · cited 1× · PMID 41588112 · DOI 10.1038/s41573-025-01349-4
Advances in the treatment of neuromyelitis optic spectrum disorder.
Yang X, Zhang S, Feng J, Qin X. · · 2025 · cited 1× · PMID 40291752 · DOI 10.1177/17562864251328276
Prospects for Development and Commercialisation of Allogeneic CAR-Based Therapies for Autoimmune Disease.
Osborne M, Maher J. · · 2025 · PMID 41463563 · DOI 10.3390/biology14121790

Verify or expand the search:

Other recruiting trials for Autoimmune Disease

Currently open trials in the same condition.

NCT07366866 — A Study of Safety, Tolerability, PK, and PD of Subcutaneous GenSci136 in Healthy Adults. · Phase 1 · recruiting
NCT06817889 — Remdesivir for the Treatment of Upper Respiratory Tract Infection Due to RSV in Immunocompromised Individuals · Phase 2 · recruiting
NCT06983964 — Safety and Efficacy of CD19 CAR-T Therapy for Recurrent/Refractory Autoimmune Diseases · NA · recruiting
NCT06993493 — Autologous CD19CAR-T Therapy for Recurrent/Refractory Autoimmune Diseases · NA · recruiting
NCT04751396 — Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Imm · recruiting

Other Bioray Laboratories trials

Trials by the same sponsor.

NCT07248176 — Universal CAR-T Cell Therapy for MM · NA · recruiting
NCT07248163 — Universal CAR-T Cell Therapy for NHL · NA · recruiting
NCT06298630 — Long-term Follow-up Study of BRL-101 for TDT · not yet recruiting
NCT06300723 — Clinical Study of BRL-101 in Severe SCD · NA · enrolling by invitation
NCT06287086 — Clinical Study on the Safety and Efficacy of BRL-101 in the Treatment of Sickle Cell Disease · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06633042 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Bioray Laboratories
Last refreshed: 12 November 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06633042.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing